AAVXF:OTCMKTS
Abivax SA
139,00 $
0,00%
(0,00) 1D
9. jul., 09:30:01 GMT -4 · USD
search
Vsi simboli
| Simbol | Cena | Sprememba | Odstotna sprememba |
|---|
insights_autoGeneriranje najpomembnejših vpogledov za AAVXF …
Tržna kapitalizacija
6,71 mrd.
Povprečni promet
0,00
Promet
0,00
52-tedenski najvišji tečaj
139,00 $
52-tedenski najnižji tečaj
71,26 $
Beta
3,09
Št. izdanih delnic
87,53 mio.
Št. zaposlenih
98
Tržna kapitalizacija
6,71 mrd.
Povprečni promet
0,00
Promet
0,00
52-tedenski najvišji tečaj
139,00 $
52-tedenski najnižji tečaj
71,26 $
Beta
3,09
Št. izdanih delnic
87,53 mio.
Št. zaposlenih
98
Novice
Iz spletnih virov in novičarskih partnerjev
www.dars.gov.et
·
pred 3 dnevi
ABVX Q2 2026 Earnings: Wider-Than-Expected Loss as Pre-Revenue Biotech Keeps Spending on Pipeline - Profit Announcement
TradingView
·
pred 3 dnevi
Abivax SA Stock 12‑Month Price Target Cut to $159.06, Implies 79% Upside
Profil
Abivax SA is a clinical stage biotechnology company focused on developing innovative treatments that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases.
Abivax has a program in clinical development with its lead drug candidate, obefazimod, to treat ulcerative colitis. Another program in Crohn’s disease is also in preparation and other potential inflammatory indications are being evaluated.
The company’s headquarters are based in Paris, France with a US office in Waltham, Massachusetts. Abivax’s Research and development work is conducted at its research center based in Montpellier, France. Wikipedia
Vizitka: Abivax SA
Generalni direktorMarc de Garidel | Hartmut J. Ehrlich
Št. zaposlenih98
Ustanovljeno4. dec. 2013
Sedež-
Sektor-
Spletno mestoabivax.com